WHO Pharmaceuticals Newsletter 1998, No. 09&10
(1998; 23 pages)
Índice de contenido
Cerrar esta carpetaRegulatory decisions
Ver el documentoAlbumin (human) B batches withdrawn: increase in aluminium level: Austria
Ver el documentoAstemizole - warning concerning arrhythmias: Brazil
Ver el documentoChlormezanone - withdrawn: Zimbabwe
Ver el documentoChlorzoxazone - warning: hepatotoxicity: Chile
Ver el documentoCidofovir - adverse reactions: nephrotoxicity, uveitis/iritis and hearing loss: Gilead Sciences, USA
Ver el documentoFenfluramine and dexfenfluramine - temporary suspension: Brazil
Ver el documentoFenfluramine and dexfenfluramine - warning concerning adverse reactions: Chile
Ver el documentoIonic contrast media - notice of withdrawal: Germany
Ver el documentoLaxatives containing aloe, bisacodyl, cascara sagrada and senna - proposed reclassification: USA
Ver el documentoMeloxicam - data sheet revised: gastrointestinal and skin reactions: UK
Ver el documentoMetamizole sodium - withdrawn due to agranulocytosis: Zimbabwe
Ver el documentoMibefradil - suspended: Germany
Ver el documentoNifedipine - re-approved in myocardial infarction: New Zealand
Ver el documentoPsorial ointment - sales prohibited: undeclared cortisone ingredients: Sweden
Ver el documentoPsorigon cream & lotion - withdrawn: undeclared cortisone ingredients: Germany, USA
Ver el documentoTiclopidine - revised data sheet: thrombotic thrombocytopenic purpura: Roche, USA
Ver el documentoTroglitazone - revised instructions for use: Parke-Davis, USA
Ver el documentoVitamin A and betacarotene - labelling claim prohibited: USA
Abrir esta carpeta y ver su contenidoDrug surveillance
Abrir esta carpeta y ver su contenidoNew developments
Abrir esta carpeta y ver su contenidoMedical devices
Abrir esta carpeta y ver su contenidoGeneral information
Abrir esta carpeta y ver su contenidoMedication errors
Abrir esta carpeta y ver su contenidoVeterinary medicine
 

Albumin (human) B batches withdrawn: increase in aluminium level: Austria

Austria. The manufacturer of human albumin 20% and 25% (Haemoderivate: Immuno) has voluntarily recalled these products because the pharmacopoeial specification for aluminium (200 micrograms/L or less) for treatment of premature infants and dialysis patients cannot be guaranteed over the whole shelf life of 3 years when stored at temperatures above 8EC.

The increase in aluminium content over the shelf life period is due to the fact that the glass vial releases aluminium ions. This process is catalyzed by the residual citrate content of albumin preparations and depends on storage temperature as well as on the relation of inner glass surface to the amount of liquid. For 10 ml bottles, stability of the aluminium content below 200 micrograms/l cannot be guaranteed for the shelf life, irrespective of storage conditions.

In 50 ml and 100 ml bottles stored at temperatures below 8EC, the increase in aluminium content is sufficiently slowed down so that it does not rise beyond 200 micrograms/l within the 3-year shelf life. However, at storage temperatures exceeding 8EC (room temperature), the aluminium content may increase beyond 200 micrograms/l. According to available stability studies, this threshold value is not surpassed before 12 months of storage at these higher temperatures.

References: EU/EEA Rapid Alert - Defective Product Recall dated 22 September 1998, Pharmacovigilance Section, Federal Ministry of Labour, Health and Social Affairs, Vienna.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013